Glycated hemoglobin levels and risk of all-cause and cause-specific mortality in hemodialysis patients with diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dae Kyu | - |
dc.contributor.author | Ko, Gang Jee | - |
dc.contributor.author | Choi, Yun Jin | - |
dc.contributor.author | Jeong, Kyung Hwan | - |
dc.contributor.author | Moon, Ju Young | - |
dc.contributor.author | Lee, Sang Ho | - |
dc.contributor.author | Hwang, Hyeon Seok | - |
dc.date.accessioned | 2022-11-16T02:40:19Z | - |
dc.date.available | 2022-11-16T02:40:19Z | - |
dc.date.created | 2022-11-15 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 0168-8227 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/145545 | - |
dc.description.abstract | Aim: Adequate glycemic control is fundamental for improving clinical outcomes in hemodialysis patients with diabetes. However, the target for glycated hemoglobin (HbA1c) level and whether cause-specific mortality differs based on HbA1c levels remain unclear. Methods: A total of 24,243 HD patients with diabetes were enrolled from a multicenter, nationwide registry. We examined the association between HbA1c levels and the risk of all-cause and cause-specific mortality. Results: Compared to patients with HbA1c 6.5%-7.5%, patients with HbA1c 8.5-9.5% and >= 9.5% were associated with a 1.26-fold (95% CI, 1.12-1.42) and 1.56-fold (95% CI, 1.37-1.77) risk for all-cause mortality. The risk of all-cause mortality did not increase in patients with HbA1c < 5.5%. In cause-specific mortality, the risk of cardiovascular deaths significantly increased from small increase of HbA1c levels. However, the risk of other causes of death increased only in patients with HbA1c > 9.5%. The slope of HR increase with increasing HbA1c levels was significantly faster for cardiovascular causes than for other causes. Conclusions: There was a linear relationship between HbA1c levels and risk of all-cause mortality in hemodialysis patients, and the risk of cardiovascular death increased earlier and more rapidly, with increasing HbA1c levels, compared with other causes of death. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | GLYCEMIC CONTROL | - |
dc.subject | GLUCOSE | - |
dc.subject | DEATH | - |
dc.subject | A(1C) | - |
dc.subject | INDIVIDUALS | - |
dc.subject | ASSOCIATION | - |
dc.subject | GUIDELINE | - |
dc.subject | INDEX | - |
dc.subject | A1C | - |
dc.title | Glycated hemoglobin levels and risk of all-cause and cause-specific mortality in hemodialysis patients with diabetes | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ko, Gang Jee | - |
dc.identifier.doi | 10.1016/j.diabres.2022.110016 | - |
dc.identifier.scopusid | 2-s2.0-85135049798 | - |
dc.identifier.wosid | 000862757000006 | - |
dc.identifier.bibliographicCitation | DIABETES RESEARCH AND CLINICAL PRACTICE, v.190 | - |
dc.relation.isPartOf | DIABETES RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.title | DIABETES RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.volume | 190 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | GLUCOSE | - |
dc.subject.keywordPlus | DEATH | - |
dc.subject.keywordPlus | A(1C) | - |
dc.subject.keywordPlus | INDIVIDUALS | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | GUIDELINE | - |
dc.subject.keywordPlus | INDEX | - |
dc.subject.keywordPlus | A1C | - |
dc.subject.keywordAuthor | HbA(1c) | - |
dc.subject.keywordAuthor | Hemodialysis | - |
dc.subject.keywordAuthor | All-cause death | - |
dc.subject.keywordAuthor | Cause-specific mortality | - |
dc.subject.keywordAuthor | Cardiovascular death | - |
dc.subject.keywordAuthor | End-stage kidney disease | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.